Normal view MARC view ISBD view

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer

In British Journal of Cancer
By: Oh, S. C.
Contributor(s): Choi, I. K | Park, K. H | .
Material type: materialTypeLabelArticleSeries: Vol 92 Issues 5.Publisher: 2005Description: 827-831.Subject(s): stomach neoplasms | UFT | cisplatin | docetaxel | DDC classification: In: British Journal of CancerSummary: We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m-2 intravenously (i.v.) for 1 h and then cisplatin 75 mg m-2 i.v. for 2 h on day 1. Oral UFT at 400-600 mg day-1, as determined by body surface area, and leucovorin at 75 mg day-1 were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4-63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156+ weeks), median survival d
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Oh,/Par Available AR5645

We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m-2 intravenously (i.v.) for 1 h and then cisplatin 75 mg m-2 i.v. for 2 h on day 1. Oral UFT at 400-600 mg day-1, as determined by body surface area, and leucovorin at 75 mg day-1 were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4-63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156+ weeks), median survival d

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha